BFAI (5,6-Benzofuranyl-2-aminoindane) is a drug that acts as a serotonin releasing agent (SSRA) and produces entactogen effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.[1]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C11H11NO |
Molar mass | 173.215 g·mol−1 |
3D model (JSmol) | |
| |
|
See also edit
References edit
- ^ WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc.